Katherine Anagnostou

Katherine Anagnostou

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2018 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
AKAtoosa Kourosh
Atoosa Kourosh
RLRuth A. Luna
Ruth A. Luna
MBMiriam Balderas
Miriam Balderas
CNChristina Nance
Christina Nance
KAKatherine Anagnostou
Katherine Anagnostou
CDCarla M. Davis
Carla M. Davis

1 April 2019 in Annals of Allergy, Asthma & Immunology
Verified
Journal Article
Closed access
ABAndrea C. Blackman
Andrea C. Blackman
SASara Anvari
Sara Anvari
CDCarla M. Davis
Carla M. Davis
KAKatherine Anagnostou
Katherine Anagnostou

5 February 2019 in Children
Verified
Journal Article
Open access
PDF file
HWHelen Wang
Helen Wang
SASara Anvari
Sara Anvari
KAKatherine Anagnostou
Katherine Anagnostou
The prevalence of allergic disorders has been increasing worldwide and significantly impacts the quality of life of the atopic individual. There has been an increased interest in the role of probiotics for the prevention and treatment of allergic disorders, given the recent evidence that atopy risk may be associated with a dysbiosis of the gut microbiome. Research in this area is ongoing with some studies showing possible benefits of probiotics, with seemingly little to no risk. While these studies suggest that there may be a promise in probiotic use for the prevention or treatment of allergy, further evidence is needed to determine its efficacy, optimal dosing, and strains needed for treatment. In this review, we discuss recently published studies examining the benefits, risks, and role of probiotics in preventing atopic dermatitis, asthma, allergic rhinitis, and food allergy.

1 January 2020 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
KAKatherine Anagnostou
Katherine Anagnostou
JHJonathan O’b. Hourihane
Jonathan O’b. Hourihane
MGMatthew Greenhawt
Matthew Greenhawt

26 May 2020 in Children
Verified
Journal Article
Open access
PDF file
CNChristina L. Nance
Christina L. Nance
RDRoman Deniskin
Roman Deniskin
VDVeronica C. Diaz
Veronica C. Diaz
MPMisu Paul
Misu Paul
SASara Anvari
Sara Anvari
KAKatherine Anagnostou
Katherine Anagnostou
Food allergies are common and estimated to affect 8% of children and 11% of adults in the United States. They pose a significant burden—physical, economic and social—to those affected. There is currently no available cure for food allergies. Emerging evidence suggests that the microbiome contributes to the development and manifestations of atopic disease. According to the hygiene hypothesis, children growing up with older siblings have a lower incidence of allergic disease compared with children from smaller families, due to their early exposure to microbes in the home. Research has also demonstrated that certain environmental exposures, such as a farming environment, during early life are associated with a diverse bacterial experience and reduced risk of allergic sensitization. Dysregulation in the homeostatic interaction between the host and the microbiome or gut dysbiosis appears to precede the development of food allergy, and the timing of such dysbiosis is critical. The microbiome affects food tolerance via the secretion of microbial metabolites (e.g., short chain fatty acids) and the expression of microbial cellular components. Understanding the biology of the microbiome and how it interacts with the host to maintain gut homeostasis is helpful in developing smarter therapeutic approaches. There are ongoing trials evaluating the benefits of probiotics and prebiotics, for the prevention and treatment of atopic diseases to correct the dysbiosis. However, the routine use of probiotics as an intervention for preventing allergic disease is not currently recommended. A new approach in microbial intervention is to attempt a more general modification of the gut microbiome, such as with fecal microbiota transplantation. Developing targeted bacterial therapies for food allergy may be promising for both the treatment and prevention of food allergy. Similarly, fecal microbiota transplantation is being explored as a potentially beneficial interventional approach. Overall, targeted bacterial therapies for food allergy may be promising for both the treatment and prevention of food allergy.

1 April 2020 in Annals of Allergy, Asthma & Immunology
Verified
Journal Article
Closed access
JMJennifer Miller
Jennifer Miller
ABAndrea C. Blackman
Andrea C. Blackman
HWHelen T. Wang
Helen T. Wang
SASara Anvari
Sara Anvari
MJMichelle Joseph
Michelle Joseph
KAKatherine Anagnostou
Katherine Anagnostou